

Metabolic alterations and redox homeostasis in ferroptosis: emerging mechanisms and therapeutic implications

Mirjana Macvanin¹, Dušan Spasić², Sanja Gluscevic³, Tatjana Srdić-Rajić⁴, Aleksandra Klisic^{5,6*}

¹Institute of Chemistry, Technology and Metallurgy, Center for Chemistry, National Institute of the Republic of Serbia, University of Belgrade, Serbia

²University of Belgrade – Faculty of Medicine, Department of Pharmacology, Clinical Pharmacology and Toxicology, Belgrade, Serbia

³Clinical Center of Montenegro, Department of Neurology, Podgorica, Montenegro

⁴Institute for Oncology and Radiology of Serbia, Department of Experimental Oncology, Belgrade, Serbia

⁵University of Montenegro, Faculty of Medicine, Podgorica, Montenegro

⁶Center for Laboratory Diagnostics, Primary Health Care Center, Podgorica, Montenegro

***Corresponding author:**

Aleksandra Klisic MD PhD

University of Montenegro

Faculty of Medicine

Center for Laboratory

Diagnostics

Primary Health Care Center

Trg Nikole Kovacevica 6

81000 Podgorica

Montenegro

Phone/fax: +382 20 481 999

E-mail: aleksandraklisic@gmail.com

Submitted: 21 March 2026; **Accepted:** 26 June 2026

Online publication: 20 August 2026

Arch Med Sci 2026; 22 (4): 2231–2249

DOI: <https://doi.org/10.5114/aoms/225096>

Copyright © 2026 Termedia & Banach

Abstract

Ferroptosis is a programmed cell death characterized by excessive, iron-dependent accumulation of membrane lipid peroxides due to insufficient glutathione-dependent antioxidant defense. It is influenced by the metabolism of amino acids, lipids, and iron, and occurs in conditions of decreased glutathione peroxidase 4 (GPX4) activity. The increased polyunsaturated fatty acid (PUFA) content in membrane phospholipids is associated with cellular hypersusceptibility to ferroptosis. In contrast, incorporation of monounsaturated fatty acids may protect cells against ferroptotic cell death. Cellular sensitivity to ferroptosis is additionally influenced by glutamine catabolism and the xc⁻-system-mediated import of cystine, which modulate glutathione production, and by elevated iron levels, which lead to the buildup of reactive oxygen species (ROS) that attack membrane-localized PUFAs. This review focuses on recent findings of perturbed metabolic processes in cancer that create a high iron demand and an altered lipid composition, thereby predisposing cells to ferroptosis. We analyze the therapeutic potential of pharmacological agents that can selectively trigger ferroptosis in tumor cells.

Key words: ferroptosis, glutathione metabolism, GPX4, lipid metabolism, iron metabolism, redox homeostasis, cancer therapeutics.

Introduction

Ferroptosis is a programmed cell death driven by iron-dependent lipid peroxidation [1, 2]. The hallmarks of ferroptosis are reduced glutathione peroxidase 4 (GPX4) activity and an inadequate glutathione (GSH)-dependent antioxidant response, ultimately leading to the excessive accumulation of membrane lipid peroxides. The buildup of polyunsaturated fatty acids (PUFAs), along with excessive iron and reactive oxygen species (ROS) generation, drives ferroptosis, which is accompa-

nied by specific morphological changes not seen in apoptotic cells. For example, apoptotic cells are characterized by chromatin condensation, membrane blebbing, and mitochondrial outer membrane permeabilization, whereas ferroptotic cells display condensed mitochondria with reduced cristae [3].

The proportion of PUFAs in the cell membrane determines how sensitive the cell is to ferroptosis. Incorporation of PUFAs into membrane phospholipids depends on the activities of acetyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3). Acetyl-CoA synthetase long-chain family member 3 (ACSL3), however, directs the synthesis of monounsaturated fatty acids (MUFAs) that inhibit ferroptosis by reducing membrane PUFAs. Mechanistically, ferroptosis occurs at the intersection of three processes: metabolic reprogramming of lipid and amino acid pathways, ROS generation via the Fenton reaction, and dysregulation of iron homeostasis via transferrin receptor-mediated uptake [4, 5].

The selenium (Se)-dependent enzyme GPX4 is required to maintain cell membrane integrity and prevent ferroptosis. By converting membrane phospholipid hydroperoxides into non-toxic lipid alcohols, GPX4 acts as the main defense against lipid peroxidation. When GPX4 is absent, lipid peroxides accumulate excessively and can trigger a chain reaction of membrane lipid oxidation leading to ferroptotic cell death [6, 7]. GPX4 becomes inactive when GSH is depleted or upon inhibition of the cystine/glutamate antiporter system xc⁻, which consists of a light chain, also known as SLC7A11, and a heavy chain, SLC3A2 [8, 9]. Cells treated with GPX4 inhibitors become highly sensitive to ferroptosis, which has important therapeutic implications, especially for cancer, where GPX4 is crucial for tumor cell survival. GPX4 also plays a role in the homeostasis of immune cells. In the absence of GPX4, T regulatory (Treg) cells accumulate lipid peroxides and undergo ferroptosis. This reduction of Treg cell suppression may enhance antitumor immunity [10].

Here, we analyze the interplay between iron, lipid, and amino acid metabolism in ferroptosis and describe how ferroptosis-associated metabolic alterations affect cancer cells. We discuss the context-dependent effects of ferroptosis, which can contribute to tissue damage and tumor initiation, and present the major strategies that induce ferroptosis. Finally, we describe the role of ferroptosis-inducing nutrients (FINs) in cancer and outline potential future directions for translating ferroptosis-targeting strategies into effective and safe clinical therapies.

Ferroptosis-associated metabolic reprogramming

Lipid metabolism

Membrane vulnerability to oxidative damage depends on the presence of the reactive double bonds in PUFAs. Sensitivity of cells to ferroptosis is largely determined by ACSL4, an enzyme whose primary function is to mediate conversion of long-chain PUFAs into active acyl-CoA derivatives [11, 12] responsible for incorporating PUFAs such as arachidonic acid, adrenic acid, eicosapentaenoic acid, docosahexaenoic acid, epoxyeicosatrienoic acids, and hydroxyeicosatetraenoic acid into membrane phospholipids, thereby increasing the membrane's susceptibility to lipid peroxidation [13]. Apart from remodeling the cell membrane composition by enriching its PUFA-based phospholipid content, ACSL4 has been implicated in regulating the biosynthesis of eicosanoids and steroid hormones, mediating metabolic reprogramming, and promoting antitumor immunity.

ACSL4 may facilitate the cross-talk between fatty acid metabolism and ferroptosis. Fatty acyl-CoAs generated by ACSL4-catalyzed reactions can either provide energy to cells via β -fatty acid oxidation or enter the lipid biosynthesis pathway [14]. Once PUFAs are integrated into phospholipids, they can undergo oxidation enzymatically via lipoxygenases (LOXs) or through iron-dependent free radicals to produce lipid hydroperoxides. Excessive peroxidation of PUFA-containing phospholipids in the cellular membrane is the major signal that triggers ferroptosis in both normal and cancer cells [15, 16], since the oxidative attack of the carbon-carbon double bonds of PUFA-containing phospholipids leads to the rupture of cell membranes [6].

Lipid peroxides can be generated in the cell by Fe²⁺-dependent non-enzymatic Fenton reaction or by ACSL4/LPCAT3/acid-15-lipoxygenase (ALOX15)-mediated enzymatic reactions, where, upon conversion of free intracellular PUFAs into their fatty acyl-CoA form by the enzyme ACSL4, they undergo LPCAT3-mediated esterification into phospholipids. ALOX15 then converts free and esterified PUFAs into their hydroperoxide forms [6, 15–19]. Thus, ACSL4-mediated lipid peroxidation represents a promising therapeutic target that can be exploited to either protect healthy cells from oxidative injury or to induce ferroptosis in tumor cells.

Redox homeostasis and iron metabolism

The cell maintains its redox homeostasis through a balanced action of both enzymatic and non-enzymatic antioxidant systems. The GSH/GPX4 axis, the NADPH-dependent coenzyme Q₁₀

(CoQ10)/ferroptosis suppressor protein 1 (FSP1) system, and the tetrahydrobiopterin pathway [5–7] mediate protective responses against phospholipid peroxidation. The functionality of this response is determined by effective cystine absorption, mitochondrial reducing equivalents, and transcriptional regulation via stress-response pathways, such as the Nrf2-Keap1-p62 pathway.

When cystine import via system xc[−] is restricted or when pharmaceuticals inhibit GPX4 activity, cells are unable to degrade lipid hydroperoxides, leading to ROS accumulation [10, 11]. Mechanistically, ferroptosis is based on iron-driven redox catalysis where, in the Fenton reaction, ferrous iron (Fe²⁺) is converted into Fe³⁺, which leads to the formation of highly reactive •OH that targets PUFAs in membrane phospholipids [12]. The formed lipid peroxides are highly reactive and can further propagate excessive ROS accumulation in various cellular compartments, leading to oxidative damage, disruption of membrane integrity, and cell death [20, 21] (Figure 1; [22]). The exact mechanism underlying iron's involvement in ferroptosis remains unclear. However, it is established

that increased cellular free iron content is usually observed during the induction of ferroptosis [23] and that excessive heme and non-heme iron can directly induce ferroptosis [24]. In addition, iron chelators were shown to disrupt ferroptotic cell death *in vitro* and *in vivo*, whereas exogenous iron supplementation sensitizes cells to ferroptosis inducers [1].

Iron transport proteins

Transferrin (TF) is a glycoprotein that reversibly binds iron in the circulation and redirects it to various organs. TF can bind to two ferric ions (Fe³⁺), and its iron-binding properties depend on pH changes. Low plasma TF levels are observed in patients with chronic inflammation and/or liver and kidney disease [25]. Amino acid starvation experiments showed that TF is required for the induction of ferroptotic cell death, most likely due to cysteine (Cys) starvation that leads to cellular GSH depletion [26]. Gao *et al.* suggested that TF serves as a positive regulator of ferroptosis because iron-free apotransferrin or TF-free serum




Figure 1. The interplay between lipid and iron metabolism in ferroptosis

ACSL4 – acyl-CoA synthetase long-chain family member 4, CD36 – cluster differentiation 36, CoQ10 – coenzyme Q10, FSP1 – ferroptosis suppressor protein 1, GSH – glutathione, HMGCR – 3-hydroxy-3-methylglutaryl-CoA reductase, LOX – lipoxygenase, LPCAT3 – lysophosphatidylcholine acyltransferase 3, MUFA – monounsaturated fatty acid, PL-PUFA – phospholipid-containing polyunsaturated fatty acid, PUFA – polyunsaturated fatty acid, SCD1 – stearoyl-coenzyme A desaturase 1, SLC – solute carrier family, SQS – squalene synthase, STEAP – six-transmembrane epithelial antigen of the prostate metalloredox family, TXNRD – thioredoxin reductase 1.

failed to induce ferroptosis in mouse embryonic fibroblasts (MEF). In contrast, the addition of recombinant iron-containing holo-TF induced cell death in MEFs [26]. Iron-bound TF interacts with the dimeric glycoprotein transferrin receptor 1 (TfR1) on the plasma membrane, which is encoded by the TFRC gene, and the TF-TfR1 complex is internalized via receptor-mediated endocytosis. In the acidic endosomal environment, iron is reduced from Fe^{3+} to Fe^{2+} by the enzyme six-transmembrane epithelial antigen of prostate 3 (STEAP3), and released into the cytosol as TfR1 is recycled back to the cell surface. In malignant cells, increased TFRC expression reflects the high iron demand for cell growth and proliferation and is positively correlated with ferroptosis induced by erastin [27, 28] or artemisinin derivatives [29]. Yang and Stockwell reported that oncogenic Ras sensitizes cells to erastin-induced ferroptosis by increasing TFRC expression, whereas TFRC knockdown reduces sensitivity to erastin-induced ferroptosis in cells bearing a Ras mutation [30]. Additionally, TFRC knockdown inhibits Cys-depletion-induced ferroptosis [26]. TfR1 may serve as a biomarker of ferroptosis sensitivity, as the recently identified anti-TfR1 antibody, generated by immunizing mice with membrane fractions from lymphoma cells treated with the ferroptosis inducer piperazine-erastin, recognizes only ferroptotic (and not apoptotic) cells [5].

Other metal ion transporters that mediate the uptake of iron include SLC39 family members, solute carrier family 39 member 14 (SLC39A14/ZIP14) and solute carrier family 39 member 8 (SLC39A8/ZIP8), which directly transport non-transferrin-bound iron (NTBI) across the cell membrane. SLC39A8 knockout in mice causes severe anemia, hematopoiesis dysregulation, and neonatal lethality, whereas SLC39A8^{-/-} newborn mice have significantly reduced levels of iron [31]. SLC39A14 knockout in mice impairs gluconeogenesis and reduces hepatic NTBI absorption [32]. In contrast, conditional hepatic SLC39A14 knockout blocks iron accumulation in the liver and ferroptosis-mediated liver fibrosis, suggesting that SLC39A14-mediated alterations in iron content promote ferroptosis [25].

Iron storage proteins

Ferritin, a cytosolic protein complex involved in various metabolic and inflammatory processes, consists of ferritin heavy chain 1 (FTH1) and ferritin light chain (FTL), which are responsible for iron oxidation and storage. It typically consists of 24 homologous subunits that spontaneously assemble into a spherical protein shell, with each subunit carrying an active center that converts Fe^{2+} to Fe^{3+} , enabling its storage as ferrihydrite.

FTH1 confers ferroxidase activity by converting Fe^{2+} to Fe^{3+} , which is important for the incorporation of iron into the ferritin core. Ferritin exerts protective effects against ferroptosis in various animal models, as evidenced by findings that FTH1 depletion in *Drosophila* larval wing disks leads to severe growth defects due to mitochondrial dysfunction and ferroptosis [33]. Also, overexpression of mitochondrial ferritin in neuroblastoma SH-SY5Y cells was shown to inhibit erastin-induced ferroptosis [34].

The degradation of ferritin is achieved by ferritinophagy, which represents a form of nuclear receptor coactivator 4 (NCOA4)-mediated selective autophagy, as the knockdown of NCOA4 was shown to block ferritin degradation and suppress erastin-induced ferroptosis in fibroblasts and pancreatic cancer cells, while NCOA4 overexpression promotes ferroptosis by degrading ferritin [23]. Increased ferritinophagy is required for ferroptosis induced by Cys starvation [35] and implicated in promoting ferroptotic cancer cell death [36, 37]. It should be noted that lysosomal degradation of ferritin, which is independent of autophagy, also promotes dihydroartemisinin-induced ferroptotic cancer cell death, suggesting the existence of an alternative mechanism of ferritin degradation during ferroptosis [38].

Heme, present in hemoglobin and myoglobin, is a primary dietary iron source in mammals. The enzyme heme oxygenase 1 (HMOX1) facilitates the degradation of heme into the gasotransmitter carbon monoxide (CO), free iron, and biliverdin, which is further converted into bilirubin by biliverdin reductase. Although heme itself induces HMOX1 expression, a wide range of stress-related factors, including inflammatory cytokines, heat shock, endotoxins, and heavy metal exposure, also upregulate the enzyme, pointing to a potential role for HMOX1 in maintaining redox balance. HMOX1 can either activate or suppress ferroptosis depending on the cellular context. In HT1080 fibrosarcoma cells, the ferroptosis-inducing agent (FIN) erastin increases HMOX1 expression, which can be further enhanced by hemin, an HMOX1 activator, or attenuated by the HMOX1 inhibitor zinc protoporphyrin IX (Table I) [39]. Moreover, HMOX1 knockout is associated with reduced ferroptosis, whereas HMOX1 overexpression increases susceptibility to erastin-induced ferroptosis [39, 40]. However, HMOX1 can also play an anti-ferroptotic role, as illustrated by findings that decreased HMOX1 levels in liver cancer cells or renal proximal tubular cells are associated with increased sensitivity to ferroptosis [41, 42].

Propagation of lipid oxidation can be halted by GPX4-mediated enzymatic reduction or by antioxidants such as CoQ10, vitamin E, or lipophilic radical traps [14]. It should be noted that the regula-

Table I. Ferroptosis-inducing agents, their targets, and mechanisms of action

FIN	Target	Mechanism of action	Compound	Cancer type	Reference
Class I	SLC7A11	GSH depletion via inhibition of SLC7A11 activity	Erastin	Melanoma; non-small-cell lung cancer; lung adenocarcinoma; ovarian cancer; anaplastic thyroid cancer; hepatocellular carcinoma	[120–126]
			Sorafenib	Hepatocellular carcinoma; gastric cancer; clear cell renal cell carcinoma; differentiated thyroid cancer	[42, 127–129]
			IKE	Diffuse large B-cell lymphoma; sarcoma; glioblastoma; non-small-cell lung cancer	[117, 127, 130–132]
			Cyst(e)inase	Prostate cancer; breast cancer; lung cancer; pancreatic tumors; ovarian cancer	[117, 133–135]
			Gemcitabine	Pancreatic cancer; biliary tract cancer; solid tumor	[85, 136]
Class II	GPX4	GPX4 inactivation	RSL3	Fibrosarcoma; triple-negative breast cancer; hepatocellular carcinoma; lung cancer; anaplastic thyroid cancer	[17, 117, 126, 137–139]
			ML-162	Anaplastic thyroid cancer; triple-negative breast cancer	[126, 137]
			ML-210	Glioblastoma; lung cancer; non-small-cell lung cancer; head and neck cancer	[126, 140–142]
			Cisplatin	Gastric cancer; head and neck cancer; non-small-cell lung cancer	[143–146]
Class III	CoQ10	CoQ10 depletion; GPX4 degradation	FIN56	Lung cancer; glioblastoma	[111, 147, 148]
Class IV	Redox-active iron	Iron oxidation; GPX4 inactivation	Hemin	Lung cancer	[149]
			FINO2	Fibrosarcoma	[150]

FIN – ferroptosis-inducing agent, IKE – imidazole ketone erastin, RSL3 – Ras-selective lethal 3, SLC7A11 – solute carrier family 7 member 11, GPX4 – glutathione peroxidase 4, GSH – glutathione – HSPA5 – heat shock protein family A member 5.

tion of redox processes is closely linked to cellular energy utilization, as NADPH produced in the pentose-phosphate pathway enables the regeneration of GSH from glutathione disulfide (GSSG) and the reduction of oxidized CoQ10 (ubiquinone) to reduced CoQ10 (ubiquinol). Maintenance of stable NADPH levels within the mitochondrial matrix is mediated by mitochondrial nicotinamide-nucleotide transhydrogenase (NNT), which helps limit ROS leakage from the electron transport chain [17, 18]. When the supply of NADPH is exhausted due to metabolic inhibition, oncogenic reprogramming, or oxidative overload, antioxidant regeneration is impaired, allowing lipid peroxidation to proceed more readily [43].

Adaptive transcriptional programs driven by ATF4, Nrf2, and HIF-1 α are initiated under moderate oxidative stress and increase cellular antioxidant capacity, maintaining iron homeostasis by upregulating genes such as GPX4, SLC7A11, FTH1, and HMOX1 [20, 23, 24].

Although the hormetic response delays ferroptosis-induced cellular collapse, it also may con-

tribute to treatment resistance in tumors exposed to ongoing oxidative stress [25]. Cancer cells have been shown to frequently exploit these redox pathways to maintain an equilibrium that supports their growth. However, such a “redox-addicted” state could create a vulnerability to therapy, in which deliberate interference, such as blocking cystine import, inhibiting GPX4, or disrupting NADPH recycling, can trigger ferroptosis preferentially in cancerous cells [27, 28, 44, 45].

Recent lipidomic and metabolomic analyses revealed that ferroptotic redox imbalance has important signaling consequences [46]. For instance, highly reactive and toxic secondary lipid peroxidation products, such as 4-hydroxy-2-nonenal (4-HNE) and malondialdehyde (MDA), may covalently modify proteins and trigger kinase cascades linked to autophagy, inflammation, and immune modulation [30, 47]. These findings indicate that, by interfering with immunogenic cell death, metabolic adaptation, and mitochondrial quality control, ferroptosis is closely associated with redox-dependent signaling processes.

Amino acid metabolism

Excessive availability of certain amino acids (AAs) can promote ROS generation via the electron transport chain, leading to both oxidative and metabolic stress. An approach based on modulating AA metabolism to regulate ferroptosis and treat various pathophysiological conditions has been explored in preclinical and clinical studies [48, 49], and AAs were classified as either ferroptosis-promoting or ferroptosis-inhibiting factors. It has been observed that the impact of AAs on ferroptosis varies between different cell types and requires the involvement of multiple regulatory factors, such as mammalian target of rapamycin complex 1 (mTOR), activating transcription factor 4, nuclear factor E2-related factor 2 (Nrf2), and hypoxia-inducible factor 1 α (HIF-1 α) [50–55]. When AAs are present in sufficient quantity in cells, mTORC1 localizes to the lysosome for activation by Rag GTPases [54]. In addition, some transcription factors and stress-responsive proteins, such as methyltransferase-like protein 16 (SAMTOR), an S-adenosylmethionine (SAM) sensor, cytosolic arginine sensor for mTORC1 subunit 1 (CASTOR1), and sestrin 2, can sense the cellular contents of methionine (Met), Arg, and leucine (Leu), respectively [56–58]. Growing evidence supports the important role of sestrin 2 in mediating resistance to ferroptosis through mTORC1 and Nrf2 activation in several disease models [59–62]. It should be noted that the functions of amino acid-sensing proteins are general and cannot be correlated to the effect of specific AAs on ferroptosis.

Ferroptosis-promoting amino acids

The differences in cellular AA profiles primarily reflect differential expression of metabolic enzymes or specific AA transporters across cell types [63, 64]. For instance, most cancer cells depend on glutamine (Gln) to replenish the TCA cycle during aerobic glycolysis, which is paradoxical, as Gln is an abundant, nonessential AA that can be synthesized from glucose [65, 66]. Excessive Gln catabolism may result in disruption of the TCA cycle and the electron transport chain, hyperpolarization of the mitochondrial membrane potential, and accumulation of lipid peroxides. In contrast, the inhibition of Gln catabolism confers resistance to ferroptosis [67]. Thus, the high Gln uptake rate observed in Gln-dependent cancer cells cannot be solely explained by its role as a nitrogen donor in AA and nucleotide biosynthesis and reflects additional, important Gln roles in cancer cells, such as maintaining mTOR kinase activation, mitochondrial membrane potential, and nicotinamide adenine dinucleotide phosphate (NADPH) production for redox homeostasis and synthesis

of macromolecules [68]. Suzuki *et al.* reported that glutaminase 2 (GLS2), a central regulator of glutaminolysis, suppresses HCC progression *in vivo* by promoting ferroptosis through α -ketoglutarate (α -KG)-dependent lipid ROS production, suggesting that GLS2 acts as a tumor suppressor [69]. In oral squamous cell carcinoma, the Gln transporter promotes ferroptosis by augmenting the Gln flux to the TCA cycle [70]. Furthermore, Prange *et al.* demonstrated that Gln restriction enhances the cytotoxicity of immune cells against tumor cells, thereby inhibiting tumor cell proliferation [71]. However, unlike cancer cells, adult cardiomyocytes predominantly rely on fatty acid metabolism [72]. In pathophysiological states, such as pulmonary arterial hypertension, activation of the MYC oncogene upregulates the expression of the Gln transporters SLC1A5 and SLC7A5, driving right ventricular hypertrophy through Gln catabolism. Interestingly, GLS inhibition in cardiomyocytes does not alleviate oxidative stress in these cells [65, 73].

Solute carrier family 38 member 1 (SLC38A1) and SLC1A5 can increase the intracellular availability of glutamine, which contributes to production of glutamate (Glu), which can be exchanged with cystine through SLC7A11. Inhibition of SLC7A11 is associated with ferroptosis because it reduces cystine uptake, leading to depletion of intracellular cysteine (Cys) and accumulation of glutamate [65] (Figure 2 [22]). Glu accumulation induced by a system xc⁻ inhibitor in lung adenocarcinoma sensitizes cells to ferroptosis via suppression of adenylate cyclase 10 (ADCY10)-dependent Yes-associated protein 1 (YAP1) signaling [74].

Tumor cells also often have high metabolic demands for branched-chain AAs (BCAAs) and Met. BCAAs are metabolized by transaminases BCAT1 (mainly expressed in the mitochondria) and BCAT2 (predominantly expressed in the cytosol) [73] upon being transported into cells through L-type AA transporters. BCAT2 has been reported as a novel inhibitor of ferroptosis. A recent study, using a high-throughput CRISPR/Cas9-based genetic screen in HCC cells to identify ferroptosis-inhibiting proteins, identified BCAT2 as a ferroptosis suppressor. BCAT2 activation by ectopic expression protected liver and pancreatic cancer cells from ferroptosis, both *in vitro* and *in vivo*, by specifically antagonizing system xc⁻ inhibition, whereas RNA interference-mediated inhibition triggered ferroptosis [75].

Increased Met metabolism is indicated by upregulation of methionine adenosyltransferase 2A (MAT2A) activity and solute carrier family 43 member 2 expression in tumor cells, resulting in inhibition of the antitumor activity of CD8⁺ T cells [76]. In lung and pancreatic cancer, KRAS (Kirsten




Figure 2. Amino acid metabolism pathways that promote or inhibit ferroptosis

AAs – amino acids, ACSL3 – acyl-CoA synthetase long-chain family member 3, CBS – cystathionine beta-synthase, CSE – cystathionine gamma-lyase, GCLC – glutamate-cysteine ligase catalytic subunit, GSH – reduced glutathione, GSS – glutathione synthetase, GPX4 – glutathione peroxidase 4, 3PG – 3-phosphoglycerate, PHGDH – phosphoglycerate dehydrogenase, SAM – S-adenosylmethionine, SLC38A1 – solute carrier family 38 member 1, SLC1A5 – solute carrier family 1 member 5, SLC7A11 – solute carrier family 7 member 11, SLC3A2 – solute carrier family 3 member 2.

rat sarcoma viral oncogene homolog) mutations promote BCAA metabolism [77].

Ferroptosis-inhibiting amino acids

As substrates of GSH synthesis, glycine (Gly) and Cys can regulate GPX4-mediated antioxidant defense. Gly uptake, synthesis, and catabolism are regulated by Nrf2 and are associated with tumorigenesis and malignancy [78]. Gly can inhibit ferroptosis in various disease models, and its transporter, GLYT1, is induced by Nrf2 and may contribute to reduced ROS production. The GLYT1 inhibitor bitopertin has been reported to increase Nrf2 stability by inhibiting Kelch-like ECH-associated protein 1 (Keap1)-mediated Nrf2 ubiquitination [79]. However, prolonged and excessive exposure of cells to Gly leads to GSH depletion and accumulation of lipid peroxidation products, which may be due to Gly-induced methylation, as Gly has been shown to promote SAM-mediated methylation of the GPX4 promoter [80].

Cys is required for the production of α -KG, pyruvate, and taurine. *In vivo* studies of conversion of Cys to taurine by Cys dioxygenase type 1 (CDO1)

indicated that CDO1 overexpression renders cells susceptible to ferroptosis due to reduced intracellular GSH levels [81, 82]. Cys extracellular uptake is mediated by the Cys/Glu antiporter SLC7A11, which imports one cystine molecule in exchange for an intracellular Glu molecule [83] (Figure 2). If extracellular Cys is depleted, homocysteine is synthesized *de novo* through the activities of cystathionine β -synthase and cystathionine γ -lyase in the Met-mediated sulfur transfer pathway, which also induces Cys release in lysosomes through the ATF4/AhR-mediated amino acid starvation response [84].

Glutathione and GPX4 axis

The GSH/GPX4 axis integrates amino acid, redox, and Se metabolism into a unified defense against lipid peroxidation. GSH, a tripeptide consisting of Glu, Cys, and Gly, is the primary antioxidant within cells and acts as a cofactor for GPX4. System xc⁻ mediates the exchange of intracellular Glu for extracellular cystine, which is converted into Cys upon entering the cell through NADPH-dependent thiol-disulfide exchange reac-

tions, accelerated by glutathione reductase (GSR) and thioredoxin (Trx) systems [37, 85] (Figure 2). GSH is formed in two consecutive ATP-dependent reactions in which γ -glutamylcysteine ligase (GCL) condenses Cys with Glu, whereas glutathione synthetase (GSS) ligates it with Gly [4]. GSH maintains thiol homeostasis and redox signaling by detoxifying hydrogen peroxide and lipid hydroperoxides under physiological conditions [5]. GPX4 facilitates the two-electron reduction of phospholipid hydroperoxides (PLOOHs) to their respective alcohols (PLOHs), using two molecules of GSH as electron donors. GSH is converted into GSSG during this process [86]. GSR utilizes NADPH to convert GSSG back into GSH [5, 6]. This redox cycle inhibits the propagation of lipid radical chain reactions, preventing potential membrane damage. As GSH levels decrease or GPX4 activity is inhibited, PLOOHs accumulate and subsequently decompose into reactive aldehydes such as 4-HNE and MDA. Decreased GPX4 levels may result from perturbed activity of enzymes involved in selenoprotein synthesis, Se deficiency, or defects in the mevalonate-isopentenyl pathway [23, 43]. Additionally, post-translational modifications affecting protein stability or activity may alter ferroptotic sensitivity. For instance, the deubiquitinase OTUB1 inhibits SLC7A11 degradation, while the interaction between Beclin-1 and SLC7A11 prevents cystine uptake under stress conditions [87]. MDA and 4-HNE represent important markers of lipid peroxidation associated with ferroptosis, as their accumulation is associated with increased membrane permeability, membrane disruption, and, ultimately, ferroptotic cell death [6, 10].

Another emerging ferroptosis suppressor that has demonstrated a protective effect against iron-induced cell death in conditions of GPX4 deficiency is FSP1, which primarily functions as a membrane lipid radical-scavenging system [88]. A recent study by Doll *et al.* showed that lipid radicals can be captured independently of GPX4 through the FSP1-CoQ10-NADPH pathway that restores reduced CoQ10 at the plasma membrane [24, 89], thus providing an alternative defense mechanism against GPX4 deficiency (Figure 2). The inhibitory effect of FSP1 on ferroptosis is mediated via the reduced form of CoQ10, ubiquinol, which scavenges lipid-derived radicals [89]. FSP1 plays a role in resistance to ferroptosis in various cancer cell lines [90, 91] and developing specific inhibitors that target FSP1 and/or disrupt oncogene-mediated regulation of FSP1 expression may enhance tumor cell sensitivity to chemotherapy [92]. In addition, significantly reduced FSP1 levels were observed in several pathophysiological conditions, such as preeclampsia and cerebral ischemia/reperfusion (I/R) injury [93, 94]. FSP1 over-

expression significantly stimulated the PI3K/AKT/GSK3 β pathway and enhanced resistance to ferroptosis, suggesting that FSP1 may represent a potential target for the treatment of I/R injury [94].

Nrf2-Keap1-p62 signaling

Nrf2 signaling is a key cellular defense mechanism that regulates iron metabolism, redox balance, and the oxidative stress response. The transcription factor Nrf2 regulates the expression of more than 200 genes by binding to antioxidant response elements in their promoter regions [1–3]. Under basal conditions, Nrf2 is confined in the cytoplasm by its repressor, Keap1, which acts as a substrate adaptor for the Cullin-3 (Cul3)-Rbx1 E3 ubiquitin ligase complex, facilitating Nrf2 ubiquitination and subsequent proteasomal degradation [4, 5]. Keap1 functions as a redox sensor due to its reactive Cys residues (Cys151, Cys273, and Cys288). ROS, lipid peroxides, or xenobiotics can alter Keap1's conformation, preventing its interaction with Nrf2 and inhibiting Nrf2 ubiquitination [6]. The stabilized Nrf2 translocates to the nucleus and forms heterodimers with small Maf proteins, which bind to antioxidant response element (ARE) sequences in the promoters of genes that provide cellular protection against oxidative stress [7, 10].

The consequence of such transcriptional reprogramming is enhanced efficacy of anti-ferroptotic pathways involved in the regulation of iron levels and antioxidant defense. Increased expression of SLC7A11, the catalytic subunit of glutamate-cysteine ligase (GCLC), GPX4, and GSS promotes cystine import into the cell via system xc⁻, and enhance glutathione production, thus facilitating the degradation of lipid peroxides [11, 12]. In addition, Nrf2 regulates the expression of FTH1, FTL, and ferroportin (SLC40A1), which sequester and export labile iron, limiting the availability of iron that can generate ROS in the Fenton reaction [95]. Nrf2 also increases the transcription of heme oxygenase-1 (HMOX1), whose byproducts, biliverdin and CO, possess radical-scavenging capabilities. Resistance to ferroptosis is augmented by the selective autophagy receptor p62/SQSTM1, which interacts with Keap1 by specifically binding to its Kelch domain. Under prolonged oxidative stress, a positive feedback loop is established in which Nrf2 increases p62 transcription, while p62 accumulation stabilizes Nrf2 [47]. Persistent Nrf2 activation caused by KEAP1 and/or CUL3 alterations is often associated with head-and-neck squamous carcinoma, non-small-cell lung carcinoma, and HCC [29, 30], and leads to increased expression of GPX4 and SLC7A11, which inhibit lipid peroxidation, thereby establishing a milieu that promotes tumor growth [96, 97].

The Nrf2-Keap1-p62 pathway interacts with several metabolic redox circuits. For instance, Nrf2 is involved in the transcriptional upregulation of glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase (PGD), and isocitrate dehydrogenase 1 (IDH1). The activity of these enzymes is mandatory for the production of NADPH, which serves as the reducing agent for the regeneration of GSH and CoQ10 from their oxidized states [23]. Dysregulation of Nrf2 signaling is associated with iron accumulation, as well as reduced GSH and decreased GPX4 expression. In murine models, hepatocytes lacking Nrf2 show enhanced vulnerability to ferroptosis induced by erastin and Ras-selective lethal 3 (RSL3), whereas deletion of Keap1 confers a protective effect [26]. Similarly, pharmacological inhibition of Nrf2 with agents such as brusatol or trigonelline has shown potential to re-sensitize tumors to ferroptosis inducers [27, 28].

In addition, recent findings report the role of Nrf2 in regulating lipid metabolism. Nrf2 was shown to suppress the expression of the enzymes ACSL4 and ALOX15, which are involved in the incorporation and oxidation of PUFAs into membrane phospholipids, thus indirectly reducing the pool of lipids available for peroxidation [32, 33, 47].

Mitochondrial ROS and NADPH systems

Mitochondria are a major intracellular source of ROS. During normal respiration, the formation of superoxide anion radical ($O_2^{\bullet-}$) principally occurs at complex I (NADH dehydrogenase) and complex III (cytochrome bc complex) and is caused by a limited quantity of electrons that escape the electron-transport chain (ETC) and interact with molecular oxygen [1, 2]. The enzymes superoxide dismutase 1 (SOD1) and superoxide dismutase 2 (SOD2), located in the intermembrane space/cytosol and mitochondrial matrix, respectively, convert $O_2^{\bullet-}$ into hydrogen peroxide [3, 4]. Perturbed mitochondrial homeostasis induced by oxygen deprivation and ETC inhibition increases electron leakage, which results in excessive ROS accumulation and mitochondrial lipid peroxidation [5–7]. Thus, mitochondrial dysfunction sensitizes cells to ferroptosis, and inhibition of oxidative phosphorylation promotes evasion of ferroptosis triggered by cystine deficiency [10, 11].

Mitochondria play a key role in heme synthesis and the assembly of iron-sulfur (Fe-S) clusters [12]. An imbalance in the mitoferrin transporter system that carries Fe^{2+} into mitochondria leads to an accumulation of Fe^{2+} in the mitochondrial labile iron pool and promotes the Fenton reaction that generates $\bullet OH$, which initiates peroxidation of polyunsaturated cardiolipins in the inner mitochondrial membrane [14]. Lipid peroxidation re-

sults in a loss of polarization of the mitochondrial inner membrane, disorganization of the cristae, and the release of pro-oxidant species into the cytosol [95].

Mitochondrial ferritin (FtMt) sequesters excess free iron, and its increased expression is associated with amelioration of oxidative damage in cardiomyocytes, neurons, and osteoblasts [98]. Also, efficient iron utilization is mediated by the iron-sulfur cluster scaffold protein IscU and iron chaperone frataxin, whose perturbations lead to excessive iron accumulation and hypersensitivity to ferroptosis [99]. These data suggest that mitochondrial iron-buffering capacity influences the outcome of adaptive cellular oxidative signaling.

The role of NADPH in protection against ferroptosis

NADPH provides essential reducing power for the function of GPX4 and FSP1. Enzymes responsible for mitochondrial NADPH production include IDH2 and NNT. IDH2 mediates the oxidative decarboxylation of isocitrate to α -KG, whereas NNT links proton motive force to the transfer of hydride equivalents from NADH to $NADP^+$ [25]. Decreased activity of either enzyme is associated with reduced mitochondrial NADPH levels, diminished GSH levels, and increased cellular susceptibility to ferroptosis [26].

Maintenance of cytoplasmic NADPH levels is mediated by the pentose phosphate pathway, which is driven by G6PD and PGD, along with ME1 and IDH1 [27]. By transcriptionally coordinating the expression of numerous antioxidant genes, Nrf2 plays a key role in linking cellular NADPH-generating pathways to antioxidant responses [28]. In conditions of cystine starvation, cells respond to the reduction of GSH by boosting the regeneration of CoQ10 through the FSP1-CoQ10-NADPH pathway. As expected, simultaneous inhibition of NNT or G6PD leads to a collapse of proferroptotic antioxidant defenses [43].

The mitochondrial TCA cycle and glutaminolysis considerably influence ferroptotic responses. Gln catabolism, mediated by enzymes GLS2 and glutamate dehydrogenase, results in the formation of α -KG and can contribute to NADH/NADPH production. However, ROS production in mitochondria is stimulated by excessive α -KG oxidation, leading to lipid peroxidation [32]. Inhibition of α -KG dehydrogenase activity or glutaminolysis reduces mitochondrial ROS production and protects cells against ferroptosis, an effect that is especially pronounced under cystine limitation [33]. Furthermore, by accelerating Gln degradation, MYC and KRAS-driven oncogenic pathways may connect metabolic perturbations to ferroptotic hypersensitivity in specific cancer cells [47].

Taken together, mitochondria play a key role in the interplay between metabolic disruption, compromised antioxidant defenses, and redox homeostasis, functioning as both generators and amplifiers of pro-ferroptotic signals. The interactions between the GSH/GPX4 axis, the Nrf2-Keap1-p62 signaling network, and mitochondrial ROS-NADPH mediate iron and cystine availability, maintain reducing equivalents through NADPH regeneration, and detoxify lipid peroxides. Further studies of the interactions between mitochondrial and metabolic circuits may reveal the bioenergetic foundations of ferroptosis, paving the way for novel therapeutic strategies targeting mitochondrial antioxidants.

Therapeutic implications of ferroptosis

The existence of strong associations between ferroptosis and metabolic and oxidative perturbations suggests that highly metabolically active cancer cells may be more predisposed to FINs due to higher iron demand and ROS accumulation [84, 100]. Some cancer cells that exhibit resistance to apoptosis and traditional therapies, such as mesenchymal and dedifferentiated cells, are highly susceptible to ferroptosis [101–103]. Interestingly, because ferroptosis can modulate tumor immunity and immune responses, targeting this pathway may represent an effective strategy to inhibit tumor initiation and progression. Interventions that modulate ferroptosis have shown high efficacy in cancer treatment [104–106]. Associations between ferroptosis and the tumor-suppressive functions of immuno- and radiotherapy [107–109] enable ferroptosis-based combination therapy to augment the effectiveness of conventional treatment, target resistant tumors, and prevent tumor recurrence. However, growing evidence suggests that ferroptosis has context-dependent effects at different stages of tumorigenesis. For example, while induction of ferroptosis may enable chronic liver disease progression to HCC, it is also implicated in limiting the development of already established HCC [110, 111]. Kim *et al.* reported that pharmacological induction of ferroptosis suppresses tumor growth more effectively when FINs are administered during early tumor development [112].

Mechanisms of ferroptosis induction by radio- and immunotherapy

Generally, ferroptosis induction for cancer therapy can be achieved through radiotherapy, immunotherapy, and/or pharmacological agents. Radiotherapy is a widely used treatment modality that delivers ionizing radiation to induce tumor cell death [113]. Radiotherapy induces ferroptosis to suppress tumor growth through multiple mecha-

nisms [108]: i) direct DNA damage by forming DNA double-strand breaks, which reduces SLC7A11 expression in an ataxia-telangiectasia mutated protein-dependent manner, leading to reduced cystine uptake and increased ferroptosis [114]. Also, DNA damage can inhibit SLC7A11 by upregulating the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS–STING) pathway and the activating transcription factor 3 (ATF3)/SLC7A11/GPX4 regulatory axis [115]; ii) increased ACSL4 expression that promotes excessive accumulation of PUFA-containing phospholipids [108]; iii) through the bystander effect, irradiated tumor cell-derived microparticles may induce ROS accumulation and ferroptosis in unirradiated neighboring cells [116]. In immunotherapy, activated CD8⁺ T cells release interferon gamma (IFN γ) and inhibit SLC7A11, thereby promoting PUFA accumulation via ACSL4 [117–119].

Pharmacological inducers of ferroptosis

In addition to radio- and immunotherapy, four classes of compounds have been identified as FINs with therapeutic potential in cancer, based on their mechanism of action (summarized in Table I) [120–150].

Several other systemic pharmacological agents approved for inflammatory, infectious, cardiometabolic diseases, and psychiatric disorders have been shown to induce ferroptosis in various cancer cells (Table I). Sulfasalazine (SAS), an anti-inflammatory drug used to treat rheumatoid arthritis, induces ferroptosis by inhibiting SLC7A11 [151, 152]. SAS enhances the therapeutic effectiveness of other chemotherapeutic agents, such as daunorubicin in acute myeloid leukemia [153] and paclitaxel in ovarian clear cell carcinoma [151, 154]. It also improves the efficacy of radiotherapy and anti-PD-1 immunotherapy by promoting ferroptosis [155, 156].

Statins reduce blood cholesterol levels but also induce ferroptosis by inhibiting the GSH/GPX4 and FSP1/CoQ10/NAD(P)H antioxidant pathways [102, 157–160]. For instance, simvastatin induces ferroptosis in cancer cells by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression, thereby downregulating the mevalonate pathway and reducing GPX4 expression [160]. In contrast, lovastatin reduces programmed death-ligand 1 (PD-L1) expression in lung cancer cells, thereby sensitizing the tumor cells to immunotherapy [161].

Dopamine receptor D2 (DRD2) antagonist haloperidol is used for the treatment of psychiatric disorders and inhibits tumor growth by inducing ferroptosis [162, 163]. In HCC, haloperidol can increase sorafenib- and erastin-induced ferroptosis by inhibiting sigma-1 receptor signaling,

which is involved in oxidative stress metabolism [164]. In glioblastoma multiforme, it enhances temozolomide-induced ferroptosis by inhibiting DRD2 [162]. Zalcitabine (2',3'-dideoxycytidine) is a nucleoside analog reverse transcriptase inhibitor that binds to mitochondrial DNA polymerase gamma and is used for the treatment of human immunodeficiency virus. In pancreatic cancer cells, zalcitabine induces ferroptosis by modulating the STING1/TMEM173-dependent DNA damage response and promoting mitochondrial DNA stress [165]. Brequinar is a dihydroorotate dehydrogenase inhibitor that affects pyrimidine synthesis. It was used to selectively block GPX4^{low} tumor growth by triggering ferroptosis. In combination with sulfasalazine, brequinar suppresses the growth of GPX4-high tumors [166]. Brequinar also acts synergistically with AMPK activators to suppress tumor growth through ferroptosis [167].

Several bioactive natural compounds, such as artemisinin, withaferin A (WA), β -elemene (β -ELE), and curcumenol, also show promise as FINs. Artemisinin, derived from the Chinese herb *Artemisia annua*, can promote ferritinophagy and increase intracellular free iron levels [44]. Its derivatives, artesunate and dihydroartemisinin, have been shown to synergize with sorafenib to induce ferroptosis in HCC [168, 169]. Dihydroartemisinin also enhances cisplatin-induced toxicity in pancreatic ductal adenocarcinoma (PDAC) [170]. WA, isolated from *Withania somnifera*, induces ferroptosis in high-risk neuroblastoma tumors via targeting and inhibiting GPX4 activity [171, 172]. WA enhanced ferroptotic responses in sorafenib-resistant HCC cells [173] and, in combination with anti-PD-1 immunotherapy and the C-X-C chemokine receptor 2 inhibitor, significantly reduced liver metastasis of colorectal cancer and improved survival in wild-type mice with liver tumors by inducing GPX4-associated ferroptosis in hepatocytes [174]. β -ELE from *Curcuma wenyujin* activates transcription factor EB-mediated lysosome degradation of GPX4 and has been shown to induce ferroptosis in NSCLC cells [175, 176]. Curcumenol exploits epigenetic mechanisms to suppress lung cancer cell growth by inducing ferroptosis via the lncRNA H19/miR-19b-3p/FTH1 axis [177].

Novel drug delivery systems, such as liposomes, hydrogels, and nanoparticles, may allow precise control of drug release while reducing toxicity to healthy tissues [178]. For example, BQR@MLipo, brequinar-loaded liposomes that target mitochondrial ferroptosis, were shown to effectively inhibit bladder cancer growth [178]. Additionally, targeted RSL3 delivery can be achieved using injectable alginate hydrogel RTFG@SA [179] or BNP@R nanoparticles that enable acid-activatable photodynamic therapy [139]. Novel nanodrug delivery

systems offer numerous advantages, including improved water solubility and cell uptake, prolonged drug circulation time, increased drug accumulation in tumors, and reduced drug toxicity [180]. At present, several nano-drugs are used in clinical applications, including doxorubicin liposomes and paclitaxel albumin nanoparticles [180, 181].

Combination therapeutic strategies

Growing evidence supports the observation that FINs can overcome resistance to certain conventional chemotherapies. For instance, RSL3 enhances the antitumor efficacy of cisplatin by increasing ROS levels and lipid peroxidation [182, 183], whereas combined treatment with sulfasalazine and erastin may overcome cisplatin resistance [143]. Several reports showed that erastin also increased the efficacy of cisplatin [183, 184], doxorubicin [185], docetaxel [186], vemurafenib [103], and temozolomide [187] in specific cancer models.

Programmed cell death 1 (PD-1)/PD-L1 immune checkpoint pathway targeting [188] represents a promising therapeutic approach. Immune checkpoint inhibitor (ICI)-based immunotherapy, such as anti-CTLA4 and anti-PD-1/PD-L1 antibodies, specifically targets dysfunctional immune cells and activates CD8⁺ T cells to eradicate tumor cells [189, 190]. A growing body of evidence demonstrates that combining ICIs with FINs can synergistically inhibit tumor growth in preclinical models [117]. Two important findings are associated with combination therapy, including FINs and ICIs: i) ferroptosis induction potentiates antitumor effects of CD8⁺ T cells; and ii) immunotherapy can promote cancer cell ferroptosis.

IFN γ derived from CD8⁺ T cells sensitizes tumor cells to ferroptosis by activating the JAK/STAT1 pathway to decrease SLC7A11 and SLC3A2 levels [117]. However, IFN γ can also induce ferroptosis by increasing ACSL4 transcription, which stimulates STAT1/IRF1-mediated arachidonic acid incorporation into C16 and C18-acyl chain-containing phospholipids [191]. Ferroptosis contributes to the therapeutic response to PD-L1 inhibition, as illustrated by findings that the ferroptosis inhibitor lipoxstatin-1 significantly diminishes the efficacy of PD-L1 inhibitors [117]. Also, restoring tumor cells' sensitivity to ferroptosis could enhance immunotherapy efficacy, as ferroptosis resistance correlates with tumor cells' unresponsiveness to ICIs. For instance, ICI-resistant TYRO3^{high} tumors can be resensitized to anti-PD1 therapy by inhibiting TYRO3-mediated Akt/Nrf2 signaling, thereby restoring ferroptosis [192]. Also, a combination of GPX4 inhibitors and anti-PD-1 therapy induced an immune response and suppressed tumor growth in immunocompetent mice bearing

triple-negative breast cancer [186]. However, it was observed that increased CD8⁺ T cell infiltration due to GPX4 inhibition-induced ferroptosis in HCC cells was counteracted by PD-L1 upregulation on tumor cells [174]. This can be explained by findings that ferroptosis triggers the infiltration of immunosuppressive myeloid-derived suppressor cells (MDSCs) through increased release of high-mobility group box-1 (HMGB1), a signaling molecule involved in the pathogenesis of chronic liver disease, thereby accelerating liver tumorigenesis [193]. In line with this finding, the triple combination of checkpoint blockade, pharmacological FINs, and MDSC suppression improves survival in wild-type mice with liver tumors and effectively inhibits liver metastasis [174]. The components of multidrug combination therapy based on FINs and immunotherapy can be tailored to enhance antitumor efficacy by eliciting a robust antitumor immune response while preventing ferroptosis-triggered immunosuppression.

Resistance to ferroptosis can contribute to radioresistance in some cancer cells, which is associated with cancer recurrence and an unfavorable prognosis [194]. Ionizing radiation can induce SLC7A11 and GPX4 to safeguard cells against ferroptosis, and growing evidence suggests that inhibiting SLC7A11 or GPX4 can sensitize radioresistant cancers to radiotherapy [111, 195]. The combination of radiotherapy with class I FINs that inhibit SLC7A11 or class II or III FINs that inhibit or deplete GPX4 (Table I) acted synergistically to induce ferroptosis [111]. Suppressors of cytokine signaling 2, which promote ubiquitination-mediated degradation of SLC7A11, have been proposed as a potential biomarker for predicting HCC radiosensitivity [196]. Multiple mechanisms operate to regulate the interplay between ferroptosis and radiosensitivity. For instance, in Keap1 mutant lung cancers refractory to radiotherapy, resistance to ferroptosis and radiotherapy is caused by upregulation of the Nrf2/FSP1 anti-ferroptosis axis [197]. In radioresistant esophageal squamous cell carcinoma, stanniocalcin 2 (STC2), which is involved in various processes of malignant tumors, activates protein methyltransferase 5 (PRMT5) and increases SLC7A11 levels, thereby enhancing resistance to ferroptosis [194].

Role of ferroptosis in non-cancer diseases

Dysregulation of ferroptosis has been linked to various neurodegenerative and cardiovascular diseases (CVDs) [198, 199]. For instance, ferroptosis has been implicated as a potential factor contributing to the progression of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). In AD, ferroptosis is associated with the presence of amyloid-beta (A β) peptides, which promote the accumulation of

redox-active iron leading to GSH depletion [198, 200]. In PD, which is characterized by loss of dopaminergic neurons in the iron-rich substantia nigra, dopamine metabolism can generate oxidative stress and ROS accumulation that facilitates ferroptosis [201]. Interestingly, PD pathology is associated with significantly reduced GSH levels in the substantia nigra, which makes these neurons vulnerable to iron-catalyzed lipid peroxidation and ferroptotic death [202].

Ferroptosis is implicated in the development and progression of atherosclerosis [203], heart failure [204], myocardial I/R injury [205], and myocardial infarction [206]. Atherosclerotic processes are associated with ferroptotic death of endothelial and foam cells, which contributes to plaque instability and rupture [203]. Also, CVDs are frequently associated with perturbed iron homeostasis. The high metabolic rate of the myocardium is accompanied by an increased rate of oxygen consumption and ROS accumulation [207]. In I/R injury, extensive lipid peroxidation is caused by the severe depletion of GSH during ischemia and the release of iron from damaged mitochondria, contributing to myocardial injury following infarction [198, 207].

Tissue function in neurodegenerative diseases and acute injuries may be preserved by inhibiting ferroptosis through sequestering iron required for lipid peroxidation [208]. Several potential therapeutic candidates that chelate the catalytically active iron have been identified, such as deferoxamine (DFO), deferiasirox (DFX), dexrazoxane (DZR), and deferiprone (DFP). DFO showed promising results in mitigating secondary brain injury [209] and protecting kidneys against I/R injury by inhibiting ferroptosis in renal tubular cells [210].

Conclusions and future perspectives

Ferroptosis was first described in 2012 [1] and, although it has been extensively investigated in several pathophysiological conditions, its exact molecular mechanisms remain incompletely elucidated [197]. Several studies have suggested that cellular susceptibility to ferroptosis is determined by metabolic state and cellular context [46, 197, 211–214]. Results of studies investigating the connections between ferroptosis and metabolism suggest that certain metabolic enzymes play important roles in multiple ferroptosis-associated metabolic pathways. For instance, ACSL3 can promote the integration of different fatty acids into triacylglycerols and phospholipids, and also direct their mitochondrial β -oxidation [197]. Another issue that should be resolved is whether lipid peroxidation occurs only in the plasma membrane [88, 215] since a recent study by von Krusenstiern *et al.* suggests that the endoplasmic reticulum membrane represents a major site of lipid peroxidation [216].

Ferroptosis-inducing pharmacological agents represent a promising therapeutic strategy for treating chemoresistant cells and/or specifically targeting drug-tolerant persister cancer cells [217–223]. However, some literature findings report that both induction and inhibition of ferroptosis contribute to the effectiveness of cancer immunotherapy, depending on the cellular context [112, 212, 218, 219]. Such a paradoxical finding requires further clarification, possibly by studying the metabolic perturbations that modulate ferroptosis in a specific cellular context. Additional challenges that should be addressed in future research include the development of standardized animal models to facilitate comparison of study results. Current models primarily rely on FINs to treat xenograft tumors and do not account for potential side effects associated with long-term FIN administration. In addition, the mechanisms of resistance to FINs are yet not well understood [46]. Since the expression of key molecules in ferroptosis, such as GSH and CoQ10, is regulated by multiple metabolic pathways, integrating transcriptomic, proteomic, metabolomic, and lipidomic studies of ferroptosis-associated pathways is necessary for future research on the role of ferroptosis in specific pathophysiological states [220]. Addressing these challenges will facilitate the development of personalized ferroptosis-based strategies for cancer treatment.

Acknowledgments

Dedicated to the memory of Professor Mihajlo B. Spasić, who pioneered the field of redox homeostasis research.

Mirjana Macvanin and Dušan Spasić contributed equally to this work and share first authorship.

Funding

This research was partially supported by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (Contract number: 451-03-33/2026-03/200026) and the Ministry of Education, Science and Innovation, Montenegro (Contract number: 01-082/22-1681/3).

Ethical approval

Not applicable.

Conflict of interest

The authors declare no conflict of interest.

References

- Dixon Scott J, Lemberg Kathryn M, Lamprecht Michael R, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* 2012; 149: 1060-72.
- Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death Differ* 2018; 25: 486-541.
- Javadov S. Mitochondria and ferroptosis. *Curr Opin Physiol* 2022; 25: 100483.
- Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. *Cell* 2022; 185: 2401-21.
- Feng H, Schorpp K, Jin J, et al. Transferrin receptor is a specific ferroptosis marker. *Cell Rep* 2020; 30: 3411-23.e7.
- Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. *Oxid Med Cell Longev* 2014; 2014: 360438.
- Xie Y, Kang R, Klionsky DJ, Tang D. GPX4 in cell death, autophagy, and disease. *Autophagy* 2023; 19: 2621-38.
- Wagner CA, Lang F, Bröer S. Function and structure of heterodimeric amino acid transporters. *Am J Physiol Cell Physiol* 2001; 281: C1077-93.
- Hang TD, Hung HM, Beckers P, et al. Structural investigation of human cystine/glutamate antiporter system x(c) (-) (Sx(c) (-)) using homology modeling and molecular dynamics. *Front Mol Biosci* 2022; 9: 1064199.
- Zhang W, Liu Y, Liao Y, Zhu C, Zou Z. GPX4, ferroptosis, and diseases. *Biomed Pharmacother* 2024; 174: 116512.
- Klett EL, Chen S, Edin ML, et al. Diminished acyl-CoA synthetase isoform 4 activity in INS 832/13 cells reduces cellular epoxyeicosatrienoic acid levels and results in impaired glucose-stimulated insulin secretion. *J Biol Chem* 2013; 288: 21618-29.
- Shimbara-Matsubayashi S, Kuwata H, Tanaka N, Kato M, Hara S. Analysis on the substrate specificity of recombinant human Acyl-CoA synthetase ACSL4 variants. *Biol Pharm Bulletin* 2019; 42: 850-5.
- Sun D, Wang L, Wu Y, et al. Lipid metabolism in ferroptosis: mechanistic insights and therapeutic potential. *Front Immunol* 2025; 16: 1545339.
- Tuohetahuntala M, Spee B, Kruitwagen HS, et al. Role of long-chain acyl-CoA synthetase 4 in formation of polyunsaturated lipid species in hepatic stellate cells. *Biochim Biophys Acta* 2015; 1851: 220-30.
- Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. *Proc Natl Acad Sci* 2016; 113: E4966-75.
- Shintoku R, Takigawa Y, Yamada K, et al. Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3. *Cancer Sci* 2017; 108: 2187-94.
- Bai Y, Meng L, Han L, et al. Lipid storage and lipophagy regulates ferroptosis. *Biochem Biophys Res Commun* 2019; 508: 997-1003.
- Dixon SJ, Winter GE, Musavi LS, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. *ACS Chem Biol* 2015; 10: 1604-9.
- Li S, Zhang G, Hu J, Tian Y, Fu X. Ferroptosis at the nexus of metabolism and metabolic diseases. *Theranostics* 2024; 14: 5826-52.
- Zaric BL, Macvanin MT, Isenovic ER. Free radicals: relationship to human diseases and potential therapeutic applications. *Int J Biochem Cell Biol* 2023; 154: 106346.

21. Piccolo M, Ferraro MG. Insight into iron, oxidative stress and ferroptosis: therapy targets for approaching anticancer strategies. *Cancers* 2024; 16: 1220.
22. Zhou Q, Meng Y, Li D, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. *Signal Transd Target Ther* 2024; 9: 55.
23. Hou W, Xie Y, Song X, et al. Autophagy promotes ferroptosis by degradation of ferritin. *Autophagy* 2016; 12: 1425-8.
24. Li Q, Han X, Lan X, et al. Inhibition of neuronal ferroptosis protects hemorrhagic brain. *JCI Insight* 2017; 2: e90777.
25. Yu Y, Jiang L, Wang H, et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. *Blood* 2020; 136: 726-39.
26. Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. *Mol Cell* 2015; 59: 298-308.
27. Song X, Xie Y, Kang R, et al. FANCD2 protects against bone marrow injury from ferroptosis. *Biochem Biophys Res Commun* 2016; 480: 443-9.
28. Wu J, Minikes AM, Gao M, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signaling. *Nature* 2019; 572: 402-6.
29. Ooko E, Saeed ME, Kadioglu O, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. *Phytomedicine* 2015; 22: 1045-54.
30. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. *Chem Biol* 2008; 15: 234-45.
31. Gálvez-Peralta M, He L, Jorge-Nebert LF, et al. ZIP8 zinc transporter: indispensable role for both multiple-organ organogenesis and hematopoiesis in utero. *PLoS One* 2012; 7: e36055.
32. Jenkitkasemwong S, Wang CY, Coffey R, et al. SLC39A14 is required for the development of hepatocellular iron overload in murine models of hereditary hemochromatosis. *Cell Metabol* 2015; 22: 138-50.
33. Mumbauer S, Pascual J. Ferritin heavy chain protects the developing wing from reactive oxygen species and ferroptosis. *PLoS Genet* 2019; 15: e1008396.
34. Wang YQ, Chang SY, Wu Q, et al. The protective role of mitochondrial ferritin on erastin-induced ferroptosis. *Front Aging Neurosci* 2016; 8: 308.
35. Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. *Cell Res* 2016; 26: 1021-32.
36. Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy-dependent cell death. *Semin Cancer Biol* 2020; 66: 89-100.
37. Liu J, Kuang F, Kroemer G, Klionsky DJ, Kang R, Tang D. Autophagy-dependent ferroptosis: machinery and regulation. *Cell Chem Biol* 2020; 27: 420-35.
38. Chen GQ, Benthani FA, Wu J, Liang D, Bian ZX. Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. *Cell Death Differ* 2020; 27: 242-54.
39. Kwon MY, Park E, Lee SJ, Chung SW. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. *Oncotarget* 2015; 6: 24393-403.
40. Chang LC, Chiang SK, Chen SE, Yu YL, Chou RH, Chang WC. Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis. *Cancer Letters* 2018; 416: 124-37.
41. Adedoyin O, Boddu R, Traylor A, et al. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. *Am J Physiol Renal Physiol* 2018; 314: F702-14.
42. Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. *Hepatology* 2016; 63: 173-84.
43. Wang H, Xie Y. Advances in ferroptosis research: a comprehensive review of mechanism exploration, drug development, and disease treatment. *Pharmaceuticals* 2025; 18: 334.
44. Ooko E, Saeed MEM, Kadioglu O, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. *Phytomedicine* 2015; 22: 1045-54.
45. Antmen SE, Yalaza C, Tuncel F, Berkesoglu M, Erden Er-turk S, Canacankatan N. Triple-negative breast cancer and ferroptosis: expression profiling of key regulatory genes. *Arch Med Sci* 2025; 21: 2079-87.
46. Kim JW, Lee JY, Oh M, Lee EW. An integrated view of lipid metabolism in ferroptosis revisited via lipidomic analysis. *Exp Mol Med* 2023; 55: 1620-31.
47. Pawłowska M, Nuskiewicz J, Jarek DJ, Woźniak A. Ferroptosis and metabolic dysregulation: emerging chemical targets in cancer and infection. *Molecules* 2025; 30: 3020.
48. Lukey MJ, Katt WP, Cerione RA. Targeting amino acid metabolism for cancer therapy. *Drug Discov Today* 2017; 22: 796-804.
49. Butler M, van der Meer LT, van Leeuwen FN. Amino acid depletion therapies: starving cancer cells to death. *Trends Endocrinol Metabol* 2021; 32: 367-81.
50. Longchamp A, Mirabella T, Arduini A, et al. Amino acid restriction triggers angiogenesis via GCN2/ATF4 regulation of VEGF and H2S production. *Cell* 2018; 173: 117-29.e14.
51. Li B, Khan MZ, Khan IM, et al. Genetics, environmental stress, and amino acid supplementation affect lactational performance via mTOR signaling pathway in bovine mammary epithelial cells. *Front Genet* 2023; 14: 1195774.
52. Samec M, Mazurakova A, Lucansky V, et al. Flavonoids attenuate cancer metabolism by modulating lipid metabolism, amino acids, ketone bodies and redox state mediated by Nrf2. *Eur J Pharmacol* 2023; 949: 175655.
53. Menendez-Montes I, Escobar B, Gomez MJ, et al. Activation of amino acid metabolic program in cardiac HIF1- α -deficient mice. *iScience* 2021; 24: 102124.
54. Napolitano G, Di Malta C, Ballabio A. Non-canonical mTORC1 signaling at the lysosome. *Trends Cell Biol* 2022; 32: 920-31.
55. Cheng X, Bian C, Zhang Y, Gu H, Chen G, Wu L. APOE suppresses osteosarcoma by modulating ferroptosis through the mTOR/Stat3 signaling pathway. *Arch Med Sci* 2025; 21: 2647-70.
56. Jiang C, Liu J, He S, et al. PRMT1 orchestrates with SAMTOR to govern mTORC1 methionine sensing via Arg-methylation of NPRL2. *Cell Metabolism* 2023; 35: 2183-99.e7.
57. Valenstein ML, Rogala KB, Lalgudi PV, et al. Structure of the nutrient-sensing hub GATOR2. *Nature* 2022; 607: 610-6.
58. Wolfson RL, Chantranupong L, Saxton RA, et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. *Science* 2016; 351: 43-8.
59. Xi X, Chen Q, Ma J, Wang X, Zhang J, Li Y. Sestrin2 ameliorates diabetic retinopathy by regulating autophagy and ferroptosis. *J Mol Histol* 2024; 55: 169-84.
60. Zhang L, Ding K, Liao S, et al. Sestrin2 reduces ferroptosis via the Keap1/Nrf2 signaling pathway after intestinal ischemia-reperfusion. *Free Rad Biol Med* 2024; 214: 115-28.

61. Park SJ, Cho SS, Kim KM, et al. Protective effect of sestrin2 against iron overload and ferroptosis-induced liver injury. *Toxicol Appl Pharmacol* 2019; 379: 114665.
62. Dong Z, Li T, Wang C, Zhou Y, Tong Z, Du X. Sestrin2 regulates endoplasmic reticulum stress dependent ferroptosis to engage pulmonary fibrosis by nuclear factor erythroid 2 related factor 2/activating transcription factor 4 (NRF2/ATF4). *J Immunol Res* 2023; 2023: 9439536.
63. Yang L, Chu Z, Liu M, et al. Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy. *J Hematol Oncol* 2023; 16: 59.
64. Yao H, Jiang W, Liao X, Wang D, Zhu H. Regulatory mechanisms of amino acids in ferroptosis. *Life Sci* 2024; 351: 122803.
65. Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. *Ann Rev Biomed Engin* 2017; 19: 163-94.
66. Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. *Nat Rev Cancer* 2016; 16: 619-34.
67. Gao M, Yi J, Zhu J, et al. Role of mitochondria in ferroptosis. *Mol Cell* 2019; 73: 354-63.e3.
68. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. *Trends Biochem Sci* 2010; 35: 427-33.
69. Suzuki S, Venkatesh D, Kanda H, et al. GLS2 is a tumor suppressor and a regulator of ferroptosis in hepatocellular carcinoma. *Cancer Res* 2022; 82: 3209-22.
70. Wang Z, Tang S, Cai L, et al. DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma. *Br J Cancer* 2024; 130: 1744-57.
71. Prange CJ, Sayed NYB, Feng B, et al. A redox-responsive prodrug for tumor-targeted glutamine restriction. *J Control Release* 2024; 368: 251-64.
72. Rodríguez-Graciani KM, Chapa-Dubocq XR, Ayala-Arroyo EJ, et al. Effects of ferroptosis on the metabolome in cardiac cells: the role of glutaminolysis. *Antioxidants* 2022; 11: 278.
73. Piao L, Fang YH, Parikh K, Ryan JJ, Toth PT, Archer SL. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. *J Mol Med* 2013; 91: 1185-97.
74. Zhang X, Yu K, Ma L, et al. Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. *Theranostics* 2021; 11: 5650-74.
75. Wang K, Zhang Z, Tsai H, et al. Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells. *Cell Death Differ* 2021; 28: 1222-36.
76. Bian Y, Li W, Kremer DM, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. *Nature* 2020; 585: 277-82.
77. Mayers JR, Torrence ME, Danai LV, et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. *Science* 2016; 353: 1161-5.
78. Jain M, Nilsson R, Sharma S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. *Science* 2012; 336: 1040-4.
79. Dong Y, Kang H, Peng R, et al. A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis. *Cell Metabol* 2024; 36: 1679-95. e6.
80. Ling H, Li M, Yang C, et al. Glycine increased ferroptosis via SAM-mediated GPX4 promoter methylation in rheumatoid arthritis. *Rheumatology* 2022; 61: 4521-34.
81. Hao S, Yu J, He W, et al. Cysteine dioxygenase 1 mediates erastin-induced ferroptosis in human gastric cancer cells. *Neoplasia* 2017; 19: 1022-32.
82. Yang J, Dai X, Xu H, Tang Q, Bi F. Regulation of ferroptosis by amino acid metabolism in cancer. *Int J Biol Sci* 2022; 18: 1695-705.
83. Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. *Nat Rev Mol Cell Biol* 2021; 22: 266-82.
84. Zhu J, Berisa M, Schwörer S, Qin W, Cross JR, Thompson CB. Transsulfuration activity can support cell growth upon extracellular cysteine limitation. *Cell Metabol* 2019; 30: 865-76.e5.
85. Zhu S, Zhang Q, Sun X, et al. HSPA5 regulates ferroptotic cell death in cancer cells. *Cancer Res* 2017; 77: 2064-77.
86. Li FJ, Long HZ, Zhou ZW, Luo HY, Xu SG, Gao LC. System X(c) (-)/GSH/GPX4 axis: an important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy. *Front Pharmacol* 2022; 13: 910292.
87. Liu J, Kang R, Tang D. Signaling pathways and defense mechanisms of ferroptosis. *FEBS J* 2022; 289: 7038-50.
88. Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature* 2019; 575: 688-92.
89. Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. *Nature* 2019; 575: 693-8.
90. Li J, Zheng S, Fan Y, Tan K. Emerging significance and therapeutic targets of ferroptosis: a potential avenue for human kidney diseases. *Cell Death Dis* 2023; 14: 628.
91. Liu W, Li Q, Zhu N, Zhang S, Jing J, Zhan J. YTHDF3-mediated m6A modification facilitates osteosarcoma progression through the FSP1-CoQ10-NAD(P)H axis to suppress ferroptosis. *Arch Med Sci* 2024. DOI: <https://doi.org/10.5114/aoms/187043>.
92. Hendricks JM, Doubrovsky CE, Wehri E, et al. Identification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis. *Cell Chem Biol* 2023; 30: 1090-103.e7.
93. Li P, Liu Y, Liao J, et al. FSP1 and CoQ10 have the potential to serve as biomarkers for severe preeclampsia. *BMC Pregnancy Childbirth* 2025; 25: 813.
94. Wu Y, Shi H, Zheng J, et al. Overexpression of FSP1 ameliorates ferroptosis via PI3K/AKT/GSK3 β pathway in PC12 cells with oxygen-glucose deprivation/reoxygenation. *Heliyon* 2023; 9: e18449.
95. Abdulkarimov N, Kokabi K, Kunz J. Ferroptosis and iron homeostasis: molecular mechanisms and neurodegenerative disease implications. *Antioxidants* 2025; 14: 527.
96. Lei Y, Jiang S. Ferroptosis: therapeutic potential and strategies in non-small cell lung cancer. *Biology* 2025; 14: 545.
97. Lee J, Seo Y. Emerging therapeutic strategies targeting GPX4-mediated ferroptosis in head and neck cancer. *Int J Mol Sci* 2025; 26: 6452.
98. Yang H, Ru K, Liu S, Zhu C, Qian A. Targeting ferroptosis: emerging insights into osteoporosis mechanisms. *Biology* 2025; 14: 1062.
99. Zhang M, Liu Z. Iron-sulfur clusters: a key factor of regulated cell death in cancer. *Oxid Med Cell Longev* 2022; 2022: 7449941.

100. Torti SV, Torti FM. Iron and cancer: more ore to be mined. *Nat Rev Cancer* 2013; 13: 342-55.
101. Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. *Nature* 2017; 551: 247-50.
102. Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. *Nature* 2017; 547: 453-7.
103. Tsoi J, Robert L, Paraiso K, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. *Cancer Cell* 2018; 33: 890-904.e5.
104. Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. *Mol Cancer* 2022; 21: 47.
105. Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. *Nat Rev Cancer* 2019; 19: 405-14.
106. Chen JJ, Galluzzi L. Fighting resilient cancers with iron. *Trends Cell Biol* 2018; 28: 77-8.
107. Beretta GL, Zaffaroni N. Radiotherapy-induced ferroptosis for cancer treatment. *Front Mol Biosci* 2023; 10: 1216733.
108. Lei G, Mao C, Yan Y, Zhuang L, Gan B. Ferroptosis, radiotherapy, and combination therapeutic strategies. *Protein Cell* 2021; 12: 836-57.
109. Zhao L, Zhou X, Xie F, et al. Ferroptosis in cancer and cancer immunotherapy. *Cancer Commun* 2022; 42: 88-116.
110. He F, Zhang P, Liu J, et al. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. *J Hepatol* 2023; 79: 362-77.
111. Tang D, Kroemer G, Kang R. Ferroptosis in hepatocellular carcinoma: from bench to bedside. *Hepatology* 2024; 80: 721-39.
112. Kim R, Hashimoto A, Markosyan N, et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. *Nature* 2022; 612: 338-46.
113. Wu Y, Song Y. Molecular mechanisms of tumor resistance to radiotherapy. *Mol Cancer* 2023; 22: 96.
114. Lang X, Green MD, Wang W, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. *Cancer Discov* 2019; 9: 1673-85.
115. Shen D, Luo J, Chen L, et al. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer. *Cancer Letters* 2022; 550: 215919.
116. Wan C, Sun Y. Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming. *Sci Adv* 2020; 6: eaay9789.
117. Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. *Nature* 2019; 569: 270-4.
118. Lei G, Zhang Y, Koppula P, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. *Cell Res* 2020; 30: 146-62.
119. Gan B. How erastin assassinates cells by ferroptosis revealed. *Protein Cell* 2023; 14: 84-6.
120. Yang Y, Luo M, Zhang K. Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma. *Nat Commun* 2020; 11: 433.
121. Wang W, Lu K, Jiang X, et al. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. *J Exp Clin Cancer Res* 2023; 42: 142.
122. Li Y, Yan H, Xu X, Liu H, Wu C, Zhao L. Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway. *Oncol Letters* 2020; 19: 323-33.
123. Cheng Q, Bao L, Li M, Chang K, Yi X. Erastin synergizes with cisplatin via ferroptosis to inhibit ovarian cancer growth in vitro and in vivo. *J Obstet Gynaecol Res* 2021; 47: 2481-91.
124. Shibata Y, Yasui H. Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo. *PLoS One* 2019; 14: e0225931.
125. Tang B, Zhu J, Wang Y, et al. Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against hcc and enhances the efficacy of the anti-PD-1/L1 response. *Adv Sci* 2023; 10: e2203973.
126. Yang Z, Huang R, Wang Y, et al. SIRT6 drives sensitivity to ferroptosis in anaplastic thyroid cancer through NCOA4-dependent autophagy. *Am J Cancer Res* 2023; 13: 464-74.
127. Ye LF, Chaudhary KR, Zandkarimi F, et al. Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers. *ACS Chem Biol* 2020; 15: 469-84.
128. Xu X, Li Y, Wu Y, et al. Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. *Redox Biol* 2023; 59: 102564.
129. Chang K, Chen Y. DPP9 stabilizes NRF2 to suppress ferroptosis and induce sorafenib resistance in clear cell renal cell carcinoma. *Cancer Res* 2023; 83: 3940-55.
130. Zhang Y, Tan H, Daniels JD, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. *Cell Chem Biol* 2019; 26: 623-33.e9.
131. Ferrada L, Barahona MJ, Vera M, Stockwell BR. Dehydroascorbic acid sensitizes cancer cells to system x(c) (-) inhibition-induced ferroptosis by promoting lipid droplet peroxidation. *Cell Death Dis* 2023; 14: 637.
132. Shan G, Bi G, Zhao G, et al. Inhibition of PKA/CREB1 pathway confers sensitivity to ferroptosis in non-small cell lung cancer. *Respir Res* 2023; 24: 277.
133. Cramer SL, Saha A, Liu J, et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. *Nat Med* 2017; 23: 120-7.
134. Alvarez SW, Sviderskiy VO, Terzi EM, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. *Nature* 2017; 551: 639-43.
135. Badgley MA, Kremer DM. Cysteine depletion induces pancreatic tumor ferroptosis in mice. *Science* 2020; 368: 85-9.
136. He H, Liang L, Huang J, et al. KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma. *Front Pharmacol* 2022; 13: 1007429.
137. Yang F, Xiao Y, Ding JH, et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. *Cell Metabol* 2023; 35: 84-100.e8.
138. Park SY, Jeong KJ, Poire A. Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer. *Cell Death Dis* 2023; 14: 532.
139. Song R, Li T, Ye J, et al. Acidity-activatable dynamic nanoparticles boosting ferroptotic cell death for immunotherapy of cancer. *Adv Materials* 2021; 33: 2101155.
140. You JH, Lee J, Roh JL. Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head

- and neck cancer cells via epithelial-mesenchymal transition. *Cancer Letters* 2021; 507: 40-54.
141. Zhou L, Chen J, Li R, et al. Metal-polyphenol-network coated prussian blue nanoparticles for synergistic ferroptosis and apoptosis via triggered GPX4 inhibition and concurrent in situ bleomycin toxicification. *Small* 2021; 17: e2103919.
 142. Hu Q, Zhu W, Du J. A GPX4-targeted photosensitizer to reverse hypoxia-induced inhibition of ferroptosis for non-small cell lung cancer therapy. *Chem Sci* 2023; 14: 9095-100.
 143. Roh JL, Kim EH, Jang HJ, Park JY, Shin D. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. *Cancer Letters* 2016; 381: 96-103.
 144. Roh JL, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. *Redox Biol* 2017; 11: 254-62.
 145. Wang Y, Zheng L, Shang W, et al. Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. *Cell Death Differ* 2022; 29: 2190-202.
 146. Zhou Z, Zhao Y, Chen S, et al. Cisplatin promotes the efficacy of immune checkpoint inhibitor therapy by inducing ferroptosis and activating neutrophils. *Front Pharmacol* 2022; 13: 870178.
 147. Zhang X, Guo Y, Li H, Han L. FIN56, a novel ferroptosis inducer, triggers lysosomal membrane permeabilization in a TFEB-dependent manner in glioblastoma. *J Cancer* 2021; 12: 6610-9.
 148. Sun Y, Berleth N, Wu W, et al. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. *Cell Death Dis* 2021; 12: 1028.
 149. He Z, Zhou H, Zhang Y, et al. Oxygen-boosted biomimetic nanoplateform for synergetic phototherapy/ferroptosis activation and reversal of immune-suppressed tumor microenvironment. *Biomaterials* 2022; 290: 121832.
 150. Gaschler MM, Andia AA, Liu H, et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. *Nat Chem Biol* 2018; 14: 507-15.
 151. Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. *Ann Rheum Dis* 2009; 68: 1146-52.
 152. Gout PW, Buckley AR, Simms CR, Bruchofsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc- cystine transporter: a new action for an old drug. *Leukemia* 2001; 15: 1633-40.
 153. Pardieu B, Pasanisi J, Ling F, et al. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. *Leukemia* 2022; 36: 1585-95.
 154. Idei U, Ohta T, Yamatani H, Seino M, Nagase S. Mechanism of cell death by combined treatment with an xCT inhibitor and paclitaxel: an alternative therapeutic strategy for patients with ovarian clear cell carcinoma. *Int J Mol Sci* 2023; 24: 11781.
 155. Lang X, Green MD. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. *Cancer Discov* 2019; 9: 1673-85.
 156. Kerkhove L, Geirnaert F, Rifi AL, et al. Repurposing sulfasalazine as a radiosensitizer in hypoxic human colorectal cancer. *Cancers* 2023; 15: 2363.
 157. Li Q, Liu C, Deng L, et al. Novel function of fluvastatin in attenuating oxidized low-density lipoprotein-induced endothelial cell ferroptosis in a glutathione peroxidase4- and cystine-glutamate antiporter-dependent manner. *Exp Ther Med* 2021; 22: 1275.
 158. Zhang Q, Qu H, Chen Y, et al. Atorvastatin induces mitochondria-dependent ferroptosis via the modulation of Nrf2-xCT/GPx4 axis. *Front Cell Develop Biol* 2022; 10: 806081.
 159. Sahebkar A, Foroutan Z, Katsiki N, Jamialahmadi T, Mantzoros CS. Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: is there a role for statin therapy? *Metabolism* 2023; 146: 155659.
 160. Yao X, Xie R, Cao Y, et al. Simvastatin induced ferroptosis for triple-negative breast cancer therapy. *J Nanobiotechnol* 2021; 19: 311.
 161. Mao W, Cai Y, Chen D, et al. Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer. *JCI Insight* 2022; 7: e161940.
 162. Bakadlag R, Jandaghi P, Hoheisel JD, Riazalhosseini Y. The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer. *Exp Opin Ther Targets* 2019; 23: 365-7.
 163. Liu Z, Jiang X, Gao L, et al. Synergistic suppression of glioblastoma cell growth by combined application of temozolomide and dopamine D2 receptor antagonists. *World Neurosurg* 2019; 128: e468-77.
 164. Bai T, Wang S, Zhao Y, Zhu R, Wang W, Sun Y. Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells. *Biochem Biophys Res Commun* 2017; 491: 919-25.
 165. Li C, Zhang Y, Liu J, Kang R, Klionsky DJ. Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death. *Autophagy* 2021; 17: 948-60.
 166. Mao C, Liu X, Zhang Y, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. *Nature* 2021; 593: 586-90.
 167. Yang C, Zhao Y, Wang L, et al. De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence. *Nat Cell Biol* 2023; 25: 836-47.
 168. Li Z, Dai H, Huang X, et al. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. *Acta Pharmacol Sin* 2021; 42: 301-10.
 169. Cui Z, Wang H, Li S, et al. Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism. *J Pharmacol Sci* 2022; 148: 73-85.
 170. Du J, Wang X, Li Y, et al. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism. *Cell Death Dis* 2021; 12: 705.
 171. Tang Q, Ren L, Liu J, et al. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis. *Cell Prolifer* 2020; 53: e12706.
 172. Hassannia B, Wiernicki B, Ingold I, et al. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. *J Clin Investig* 2018; 128: 3341-55.
 173. Zhang Y, Tan Y, Liu S, et al. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis. *Toxicol Mechanisms Methods* 2023; 33: 47-55.
 174. Conche C, Finkelmeier F. Combining ferroptosis induction with MDSC blockade renders primary tumours

- and metastases in liver sensitive to immune checkpoint blockade. *Gut* 2023; 72: 1774-82.
175. Zhai B, Zeng Y, Zeng Z, et al. Drug delivery systems for elemene, its main active ingredient β -elemene, and its derivatives in cancer therapy. *Int J Nanomed* 2018; 13: 6279-96.
176. Zhao LP, Wang HJ, Hu D, et al. β -Elemene induced ferroptosis via TFEB-mediated GPX4 degradation in EGFR wide-type non-small cell lung cancer. *J Adv Res* 2024; 62: 257-72.
177. Zhang R, Pan T, Xiang Y, et al. Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19/miR-19b-3p/FTTH1 axis. *Bioactive Materials* 2022; 13: 23-36.
178. Ding Q, Tang W, Li X, et al. Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer. *J Control Release* 2023; 363: 221-34.
179. Chen K, Gu L, Zhang Q, et al. Injectable alginate hydrogel promotes antitumor immunity through glucose oxidase and Fe³⁺ amplified RSL3-induced ferroptosis. *Carbohydrate Polymers* 2024; 326: 121643.
180. Barenholz Y. Doxil® – The first FDA-approved nano-drug: lessons learned. *J Control Release* 2012; 160: 117-34.
181. Chen YJ, Tsai CY, Cheng YM, et al. Impacts of intralipid on nanodrug abraxane therapy and on the innate immune system. *Sci Rep* 2020; 10: 2838.
182. Zhang X, Sui S, Wang L, Li H, Zhang L, Xu S. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. *J Cell Physiol* 2020; 235: 3425-37.
183. Liu Q, Wang K. The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin. *Cell Biol Int* 2019; 43: 1245-56.
184. Li M, Li S, Zhou H, et al. Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy. *Nat Commun* 2020; 11: 1126.
185. Yu Y, Xie Y, Cao L, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. *Mol Cell Oncol* 2015; 2: e1054549.
186. Zhou HH, Chen X, Cai LY, et al. Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer. *Front Oncol* 2019; 9: 1398.
187. Chen L, Li X, Liu L, Yu B, Xue Y, Liu Y. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine- γ -lyase function. *Oncol Rep* 2015; 33: 1465-74.
188. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. *Science* 2020; 367: eaax0182.
189. Philip M, Schietinger A. CD8⁺ T cell differentiation and dysfunction in cancer. *Nat Rev Immunol* 2022; 22: 209-23.
190. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. *Lancet* 2021; 398: 1002-14.
191. Liao P, Wang W, Wang W, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. *Cancer Cell* 2022; 40: 365-78.e6.
192. Jiang Z, Lim SQ, Yan M, et al. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. *J Clin Invest* 2021; 131: e139434.
193. Athavale D, Barahona I. Overexpression of HMGB1 in hepatocytes accelerates PTEN inactivation-induced liver cancer. *Hepatol Commun* 2023; 7: e0311.
194. Chandra RA, Keane FK, Voncken FEM, Thomas CR Jr. Contemporary radiotherapy: present and future. *Lancet* 2021; 398: 171-84.
195. Jiang K, Yin X, Zhang Q, et al. STC2 activates PRMT5 to induce radioresistance through DNA damage repair and ferroptosis pathways in esophageal squamous cell carcinoma. *Redox Biol* 2023; 60: 102626.
196. Chen Q, Zheng W, Guan J, et al. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. *Cell Death Differ* 2023; 30: 137-51.
197. Koppula P, Lei G. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. *Nat Commun* 2022; 13: 2206.
198. Artusi I, Rubin M, Cravin G, Cozza G. Ferroptosis in human diseases: fundamental roles and emerging therapeutic perspectives. *Antioxidants* 2025; 14: 1411.
199. Yue H, Zhan Y, Zhang Z, Liang W, Wu Z. The emerging role of ferroptosis in myocardial fibrosis of atrial fibrillation. *Arch Med Sci* 2023; 19: 507-12.
200. Everett J, Brooks J, Lermyte F, et al. Iron stored in ferritin is chemically reduced in the presence of aggregating A β (1-42). *Sci Rep* 2020; 10: 10332.
201. Rasool A, Manzoor R, Ullah K, et al. Oxidative stress and dopaminergic metabolism: a major PD pathogenic mechanism and basis of potential antioxidant therapies. *CNS Neurol Disord Drug Targets* 2024; 23: 852-64.
202. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. *Neurosci Letters* 1992; 142: 128-30.
203. Ouyang S, You J, Zhi C, et al. Ferroptosis: the potential value target in atherosclerosis. *Cell Death Dis* 2021; 12: 782.
204. Yang X, Kawasaki NK, Min J, Matsui T, Wang F. Ferroptosis in heart failure. *J Mol Cell Cardiol* 2022; 173: 141-53.
205. Luan X, Chen P, Miao L, Yuan X, Yu C, Di G. Ferroptosis in organ ischemia-reperfusion injuries: recent advancements and strategies. *Mol Cell Biochem* 2025; 480: 19-41.
206. Huang L, Wang X, Hu B, Rong S. Expression levels and clinical significance of ferroptosis-related genes in patients with myocardial infarction. *Sci Rep* 2024; 14: 1870.
207. Bugger H, Pfeil K. Mitochondrial ROS in myocardial ischemia reperfusion and remodeling. *Biochim Biophys Acta Mol Basis Dis* 2020; 1866: 165768.
208. Ru Q, Li Y, Chen L, Wu Y, Min J. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. *Signal Transduct Target Ther* 2024; 9: 271.
209. Liang Y, Wang Y, Sun C, Xiang Y, Deng Y. Deferoxamine reduces endothelial ferroptosis and protects cerebrovascular function after experimental traumatic brain injury. *Brain Res Bulletin* 2024; 207: 110878.
210. Huang H, He Z, Roberts II LJ, Salahudeen AK. Deferoxamine reduces cold-ischemic renal injury in a syngeneic kidney transplant model. *Am J Transplant* 2003; 3: 1531-7.
211. Liang D, Minikes AM, Jiang X. Ferroptosis at the intersection of lipid metabolism and cellular signaling. *Mol Cell* 2022; 82: 2215-27.
212. Mbah NE, Lyssiotis CA. Metabolic regulation of ferroptosis in the tumor microenvironment. *J Biol Chem* 2022; 298: 101617.
213. Zheng J, Conrad M. The metabolic underpinnings of ferroptosis. *Cell Metabol* 2020; 32: 920-37.

214. Fernández LP, Gómez de Cedrón M, Ramírez de Molina A. Alterations of lipid metabolism in cancer: implications in prognosis and treatment. *Front Oncol* 2020; 10: 577420.
215. Astudillo AM, Balboa MA, Balsinde J. Compartmentalized regulation of lipid signaling in oxidative stress and inflammation: plasmalogens, oxidized lipids and ferroptosis as new paradigms of bioactive lipid research. *Progress Lipid Res* 2023; 89: 101207.
216. von Krusenstiern AN, Robson RN. Identification of essential sites of lipid peroxidation in ferroptosis. *Nat Chem Biol* 2023; 19: 719-30.
217. Linkermann A, Skouta R, Himmerkus N, et al. Synchronized renal tubular cell death involves ferroptosis. *Proc Natl Acad Sci USA* 2014; 111: 16836-41.
218. Xu H, Ye D, Ren M, Zhang H, Bi F. Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. *Trends Mol Med* 2021; 27: 856-67.
219. Xu C, Sun S, Johnson T, et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of anti-tumor immunity. *Cell Rep* 2021; 35: 109235.
220. Lee J, Shin D, Roh JL. Lipid metabolism alterations and ferroptosis in cancer: paving the way for solving cancer resistance. *Eur J Pharmacol* 2023; 941: 175497.
221. Rodriguez R, Schreiber SL, Conrad M. Persister cancer cells: iron addiction and vulnerability to ferroptosis. *Mol Cell* 2022; 82: 728-40.
222. Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. *Nat Rev Cancer* 2022; 22: 381-96.
223. Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. *Cancer Cell* 2019; 35: 830-49.